Retatrutide is taken as a once-weekly subcutaneous injection, a dosing frequency shared with other leading incretin-based therapies such as semaglutide and tirzepatide. As an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, it has shown considerable promise in Phase 2 clinical trials for obesity and type 2 diabetes. However, retatrutide has not yet received approval from the MHRA or EMA and remains unavailable outside regulated clinical trials in the UK. This article outlines what is currently known about its dosing, mechanism, suitability, safety profile, and regulatory status.

How Often Is Retatrutide Taken and What Doses Are Used?

Retatrutide is taken once weekly by subcutaneous injection, with doses escalated stepwise from a low starting dose; Phase 2 trials studied up to 12 mg weekly, but no approved dosing regimen exists in the UK.

Retatrutide is administered as a subcutaneous injection — meaning it is injected under the skin — once weekly. This weekly dosing schedule is consistent with other agents in the incretin-based therapy class, such as semaglutide and tirzepatide, and is designed to maintain stable drug levels in the body throughout the treatment period.

In clinical trials, retatrutide has been studied across a range of investigational doses, starting at a low introductory dose and gradually escalating over several weeks. This titration approach is used to improve tolerability, particularly in relation to gastrointestinal side effects. In the published Phase 2 obesity trial (Jastreboff et al., NEJM 2023), doses of up to 12 mg once weekly were studied; Phase 3 trial regimens may differ, and specific details should be sought from the relevant trial registries (e.g., ClinicalTrials.gov).

The dose escalation approach used in research settings typically follows a structured stepwise pattern:

• Starting dose: A low dose (e.g., 1–2 mg once weekly) for the initial weeks

• Intermediate doses: Gradual increases at protocol-specified intervals

• Maintenance dose: A target dose determined by tolerability and clinical response

It is important to note that, as retatrutide is not yet approved for clinical use in the UK, there is currently no officially recommended dosing regimen for patients outside of clinical trial settings. All dosing information available at this stage is derived from investigational research and must not be used as a basis for self-administration or self-prescribing.

How Retatrutide Works in the Body

Retatrutide simultaneously activates GLP-1, GIP, and glucagon receptors, creating a triple agonist effect that reduces appetite, improves glycaemic control, and may increase energy expenditure beyond dual agonists.

Retatrutide is a novel triple receptor agonist, meaning it simultaneously activates three distinct hormone receptors involved in the regulation of appetite, blood glucose, and energy balance. Specifically, it targets the receptors for glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon. This triple mechanism of action distinguishes retatrutide from existing approved therapies, which typically act on one or two of these pathways.

GLP-1 receptor activation promotes insulin secretion in response to meals, suppresses glucagon release, slows gastric emptying, and reduces appetite by acting on satiety centres in the brain. These combined effects contribute to lower blood glucose levels and reduced caloric intake.

GIP receptor activation further enhances insulin secretion and may play a role in fat metabolism and energy storage, complementing the effects of GLP-1.

Glucagon receptor activation is a particularly distinctive feature of retatrutide. Glucagon typically raises blood glucose; however, it is hypothesised — based largely on preclinical and early clinical data — that glucagon receptor agonism, in the context of GLP-1 co-stimulation, may increase energy expenditure and promote fat breakdown (lipolysis), potentially amplifying weight loss beyond what is achievable with dual agonists alone. These mechanistic interpretations remain under active investigation in human trials.

Together, these three mechanisms are thought to create a synergistic effect on body weight and metabolic health. The Phase 2 obesity trial (Jastreboff et al., NEJM 2023) reported substantial reductions in body weight, with some participants achieving losses exceeding 20% of their baseline body weight at the highest doses studied. Research into its effects on cardiovascular risk factors and glycaemic control in type 2 diabetes is ongoing.

Who May Be Suitable for Retatrutide Treatment?

Trials have studied retatrutide in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with comorbidities; those with a history of MTC, MEN 2, pancreatitis, or pregnancy would require careful specialist assessment.

Based on the populations studied in clinical trials to date, retatrutide has been investigated primarily in adults living with obesity — defined as a body mass index (BMI) of 30 kg/m² or above — as well as in those who are overweight (BMI 27 kg/m² or above) with at least one weight-related comorbidity, such as type 2 diabetes, hypertension, or dyslipidaemia. Separate trials have also explored its use specifically in people with type 2 diabetes.

As with other agents in this class, retatrutide would likely not be appropriate for everyone. The following groups have typically been excluded from clinical trials or would require careful specialist assessment, reflecting cautions seen across related approved medicines:

• A personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2): This is a theoretical concern that has led to exclusion from trials of GLP-1 receptor agonist therapies, based on animal data. It is not currently listed as a contraindication in UK Summaries of Product Characteristics (SmPCs) for related approved agents, but specialist assessment would be warranted.

• History of pancreatitis: UK SmPCs for related medicines (e.g., semaglutide, tirzepatide) advise caution in individuals with a history of pancreatitis rather than an absolute contraindication; clinical judgement and specialist review are required.

• Pregnancy or breastfeeding, as safety data in these groups are not established.

• Severe gastrointestinal disorders that may be worsened by slowed gastric motility.

These represent areas requiring careful clinical assessment rather than definitive UK contraindications, as formal eligibility criteria for retatrutide cannot yet be established in the absence of regulatory approval.

In the UK, suitability for approved weight management medicines is assessed in line with NICE guidance — for example, NICE TA875 for semaglutide (Wegovy) and NICE TA820 for tirzepatide (Mounjaro) in type 2 diabetes — which considers BMI thresholds, comorbidities, previous attempts at lifestyle intervention, and overall clinical context. Until retatrutide receives regulatory approval, individuals interested in this treatment should discuss their circumstances with a qualified healthcare professional rather than attempting to access the drug through unregulated channels.

Possible Side Effects and Safety Considerations

The most common side effects are gastrointestinal — including nausea, vomiting, and diarrhoea — typically peaking during dose escalation; serious risks include pancreatitis, gallbladder disease, and hypoglycaemia in those on insulin or sulfonylureas.

The safety profile of retatrutide, as observed in clinical trials, shares many characteristics with other GLP-1 receptor agonist therapies currently in use. The most commonly reported side effects are gastrointestinal in nature, and these are largely attributable to the drug's effects on gastric motility and appetite regulation.

Commonly reported side effects include:

• Nausea and vomiting

• Diarrhoea or constipation

• Reduced appetite

• Abdominal discomfort or bloating

• Belching or reflux

These effects are typically most pronounced during the dose escalation phase and tend to diminish as the body adjusts to the medication. The structured titration schedule used in trials is specifically designed to minimise their impact.

More serious but less common safety considerations observed across this drug class include a potential risk of pancreatitis, gallbladder-related conditions (such as gallstones/cholelithiasis), and — based on animal studies — a theoretical concern regarding thyroid C-cell tumours, though this has not been confirmed in human trials. Retatrutide's glucagon receptor activity also introduces additional considerations around potential effects on heart rate and liver metabolism, which are being carefully monitored in ongoing research.

For people with type 2 diabetes who are also taking insulin or sulfonylureas, there is a class-related risk of hypoglycaemia (low blood glucose) when incretin-based therapies are added. Dose adjustments of insulin or sulfonylureas may be required; this should be managed by a healthcare professional.

From a patient safety perspective, individuals should seek prompt medical advice if they experience:

• Severe or persistent abdominal pain (which may indicate pancreatitis)

• Right-upper-quadrant pain, fever, or jaundice (which may indicate a gallbladder problem)

• Rapid or irregular heartbeat

• Symptoms of hypoglycaemia, such as shakiness, sweating, or confusion

• Signs of an allergic reaction, such as rash, swelling, or difficulty breathing

If you experience a suspected side effect from any medicine, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

As retatrutide is not yet approved in the UK, any product currently being marketed or sold as retatrutide outside of a regulated clinical trial has not been assessed for safety or quality by the Medicines and Healthcare products Regulatory Agency (MHRA), and its use carries significant risk.

Current Availability and Regulatory Status in the UK

Retatrutide has not received MHRA or EMA approval and is not available for clinical use in the UK; it can only be accessed legitimately through a regulated clinical trial, such as those listed on the NIHR Be Part of Research portal.

As of the time of writing, retatrutide has not received marketing authorisation from the MHRA or the European Medicines Agency (EMA) and is therefore not approved for clinical use in the United Kingdom. It remains an investigational medicine, currently being evaluated in ongoing clinical trials to establish its efficacy, safety, and optimal dosing in larger and more diverse patient populations.

The drug is being developed by Eli Lilly and Company, the same pharmaceutical manufacturer behind tirzepatide (Mounjaro), which has received MHRA approval in the UK for type 2 diabetes and, more recently, for weight management. Retatrutide's development trajectory suggests it may eventually progress through the regulatory approval process, but no confirmed timeline for a UK licence application has been publicly announced.

It is important for patients and the public to be aware that the growing demand for weight loss medications has led to an increase in unregulated online sources offering unapproved or counterfeit products. The MHRA has issued repeated warnings about the dangers of purchasing injectable medicines from unverified suppliers. Products sold outside of the regulated supply chain may be contaminated, mislabelled, or contain incorrect doses, posing serious risks to health.

If you are interested in participating in a clinical trial involving retatrutide, the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk) is the authoritative UK resource for finding relevant research studies. Your GP or specialist may also be able to advise on eligibility for trials. Participation in a properly regulated trial is currently the only legitimate route through which a patient in the UK might access this medication.

Speaking to a Healthcare Professional About Retatrutide

Your GP is the appropriate first contact for weight management support; they can discuss NICE-approved options such as semaglutide (Wegovy) or tirzepatide (Mounjaro) and advise on clinical trial eligibility for investigational treatments like retatrutide.

Given that retatrutide is not yet available as an approved treatment in the UK, conversations with a healthcare professional about this medication are best framed around understanding the current evidence, exploring approved alternatives, and discussing whether participation in a clinical trial might be appropriate.

If you are living with obesity or overweight and are seeking medical support for weight management, your GP is the most appropriate first point of contact. They can assess your overall health, review your BMI and any related conditions, and discuss the range of evidence-based options currently available. In the UK, this may include referral to a specialist weight management service or consideration of approved pharmacological treatments, in line with NICE guidance:

• Semaglutide (Wegovy) is recommended by NICE (TA875) for weight management in adults meeting defined BMI and comorbidity criteria, when used as part of a specialist weight management service.

• Tirzepatide (Mounjaro) is recommended by NICE (TA820) for adults with type 2 diabetes; its role in weight management is subject to separate and evolving NICE guidance — your clinical team can advise on the current position.

• Naltrexone/bupropion (Mysimba) is licensed in the UK for weight management but is not routinely commissioned nationally through a NICE technology appraisal; local formulary decisions and availability may vary.

• Orlistat remains available and is recommended within NICE obesity management guidance (CG189) as a first-line pharmacological option in appropriate patients.

When speaking to your doctor, it may be helpful to:

• Be open about your weight management history, including previous dietary, behavioural, and pharmacological interventions

• Ask about clinical trial eligibility if you are interested in accessing investigational treatments through a regulated pathway

• Avoid self-prescribing or purchasing any injectable weight loss product online without medical supervision

• Discuss your expectations realistically, as no medication works in isolation — lifestyle changes remain a cornerstone of sustainable weight management

Healthcare professionals are best placed to provide personalised advice based on your medical history, current medications, and individual circumstances. As the evidence base for retatrutide continues to develop, guidance from bodies such as NICE and the MHRA will evolve accordingly, and your clinical team will be able to keep you informed of any changes in availability or recommendations.

Frequently Asked Questions